This study evaluates the addition of vaginal micronized progesterone effervescent to standard treatment in the treatment of preterm labor. Half of participants will receive vaginal micronized progesterone effervescent and standard treatment, while the other half will receive only standard treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Vaginal micronized progesterone effervescent once daily until delivery
Vorapong Phupong
Bangkok, Thailand
RECRUITINGlatency period
time from preterm labor to delivery
Time frame: 13 weeks
gestational age at delivery
mean gestational age at delivery
Time frame: 13 weeks
preterm delivery less than 34 weeks
percentage of preterm delivery less than 34 weeks
Time frame: 10 weeks
preterm delivery less than 37 weeks
percentage of preterm delivery less than 37 weeks
Time frame: 13 weeks
neonatal complications
percentage of newborn with RDS, IVH, NEC, death
Time frame: 13 weeks
side effects
percentage of side effects such as headache, nausea/vomiting
Time frame: 13 weeks
compliance
percentage of complete drug use
Time frame: 13 weeks
good satisfaction
percentage of good satisfaction
Time frame: 13 weeks
good quality of life
percentage of good quality of life
Time frame: 13 weeks
Time to the recurrence of uterine contractions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
mean time to the recurrence of uterine contractions
Time frame: 13 weeks